---
title: Irbesartan + Metoprolol Succinate
description: >-
  Irbesartan + Metoprolol Succinate is primarily prescribed for the treatment of
  hypertension (high blood pressure). This fixed-dose combination merges two
  distinct antihypertensive drug classes: an Angiotensin II Receptor Blocker
  (ARB) and a Beta-blocker.  It is also used in some instances for hea...
is_banned: false
lastModified: '2025-09-22T17:22:09.405Z'
faqs:
  - q: >-
      What is the recommended dosage for Irbesartan + Metoprolol Succinate?**


      **A:** The standard starting dose for adults is one tablet of 150 mg
      irbesartan/100 mg metoprolol succinate once daily. Dosage may be adjusted
      based on individual patient response.  This combination is not typically
      recommended for children.
    a: >-
      A:** The standard starting dose for adults is one tablet of 150 mg
      irbesartan/100 mg metoprolol succinate once daily. Dosage may be adjusted
      based on individual patient response.  This combination is not typically
      recommended for children.
  - q: >-
      What are the main side effects of this drug?**


      **A:** Common side effects include dizziness, fatigue, headache, nausea,
      and slow heart rate.
    a: >-
      A:** Common side effects include dizziness, fatigue, headache, nausea, and
      slow heart rate.
  - q: >-
      Are there any serious side effects to be aware of?**


      **A:** Yes, rare but serious side effects may include angioedema, kidney
      dysfunction, and worsening heart failure.
    a: >-
      A:** Yes, rare but serious side effects may include angioedema, kidney
      dysfunction, and worsening heart failure.
  - q: >-
      What are the contraindications for this drug?**


      **A:** Contraindications include hypersensitivity to the drug components,
      heart block, severe bradycardia, cardiogenic shock, and decompensated
      heart failure.
    a: >-
      A:** Contraindications include hypersensitivity to the drug components,
      heart block, severe bradycardia, cardiogenic shock, and decompensated
      heart failure.
  - q: >-
      Can this drug be used during pregnancy or breastfeeding?**


      **A:** Irbesartan is contraindicated during the second and third
      trimesters of pregnancy.  Metoprolol should be used with caution and only
      if the potential benefit outweighs the risk. Neither drug is generally
      recommended during breastfeeding.
    a: >-
      A:** Irbesartan is contraindicated during the second and third trimesters
      of pregnancy.  Metoprolol should be used with caution and only if the
      potential benefit outweighs the risk. Neither drug is generally
      recommended during breastfeeding.
  - q: >-
      What other drugs should be avoided while taking Irbesartan + Metoprolol
      Succinate?**


      **A:** Concomitant use of other antihypertensives, calcium channel
      blockers, digoxin, insulin, NSAIDs, and CYP2D6 inhibitors may lead to drug
      interactions and should be carefully managed.
    a: >-
      A:** Concomitant use of other antihypertensives, calcium channel blockers,
      digoxin, insulin, NSAIDs, and CYP2D6 inhibitors may lead to drug
      interactions and should be carefully managed.
  - q: >-
      How should I monitor a patient on Irbesartan + Metoprolol Succinate?**


      **A:** Monitor blood pressure, heart rate, potassium levels, renal
      function, and hepatic function regularly.
    a: >-
      A:** Monitor blood pressure, heart rate, potassium levels, renal function,
      and hepatic function regularly.
  - q: >-
      What is the mechanism of action of this combination?**


      **A:** Irbesartan blocks angiotensin II receptors, while metoprolol blocks
      beta-1 receptors, leading to vasodilation and reduced cardiac output.
    a: >-
      A:** Irbesartan blocks angiotensin II receptors, while metoprolol blocks
      beta-1 receptors, leading to vasodilation and reduced cardiac output.
  - q: >-
      Is this combination safe for patients with diabetes?**


      **A:** It can be used in patients with diabetes, but careful monitoring of
      blood sugar and dose adjustments may be necessary. The combination may
      mask some symptoms of hypoglycemia.
    a: >-
      A:** It can be used in patients with diabetes, but careful monitoring of
      blood sugar and dose adjustments may be necessary. The combination may
      mask some symptoms of hypoglycemia.
  - q: >-
      What should I do if a patient experiences dizziness while taking this
      medication?**


      **A:** Advise the patient to sit or lie down until the dizziness
      subsides.  Caution them against driving or operating machinery while
      experiencing dizziness.  Consider a dose adjustment if dizziness persists.
    a: >-
      A:** Advise the patient to sit or lie down until the dizziness subsides. 
      Caution them against driving or operating machinery while experiencing
      dizziness.  Consider a dose adjustment if dizziness persists.
---
## **Usage**

Irbesartan + Metoprolol Succinate is primarily prescribed for the treatment of hypertension (high blood pressure). This fixed-dose combination merges two distinct antihypertensive drug classes: an Angiotensin II Receptor Blocker (ARB) and a Beta-blocker.  It is also used in some instances for heart failure.

- **Pharmacological Classification:** Angiotensin II Receptor Blocker (ARB) + Beta-blocker
- **Mechanism of Action:** Irbesartan, the ARB component, blocks the binding of angiotensin II to its receptors. Angiotensin II is a hormone that causes vasoconstriction (narrowing of blood vessels), leading to increased blood pressure. By blocking its action, irbesartan promotes vasodilation and lowers blood pressure. Metoprolol Succinate, a beta-1 selective blocker, reduces heart rate and the force of heart contractions, which further contributes to lowering blood pressure.

## **Alternate Names**

- Irbesartan/Metoprolol Succinate
- Co-Irbezet


## **How It Works**

- **Pharmacodynamics:** Irbesartan exerts its antihypertensive effect by blocking the vasoconstricting and aldosterone-secreting effects of angiotensin II.  Metoprolol, primarily acting on beta-1 adrenergic receptors in the heart, decreases heart rate, cardiac contractility, and cardiac output, resulting in lower blood pressure.
- **Pharmacokinetics:** Irbesartan is well-absorbed orally and undergoes hepatic metabolism. Metoprolol Succinate also exhibits good oral absorption, with the extended-release formulation providing a sustained duration of action. Both drugs are predominantly eliminated through renal excretion.
- **Mode of Action/Receptor Binding/Enzyme Inhibition/Neurotransmitter Modulation:** Irbesartan selectively binds to angiotensin II type 1 (AT1) receptors.  Metoprolol competitively blocks beta-1 adrenergic receptors in the heart.
- **Elimination Pathways:**  Both irbesartan and metoprolol are primarily excreted via the kidneys, with some hepatic metabolism for irbesartan.

## **Dosage**

### **Standard Dosage**

#### **Adults:**

The typical starting dose is one tablet of Irbesartan 150 mg/Metoprolol Succinate 100 mg once daily. Based on blood pressure response, the dosage can be adjusted, with maximum doses reaching up to 300 mg irbesartan and 200 mg metoprolol succinate.


#### **Children:**

This combination is generally not recommended for children. If deemed necessary by a physician, dosage and usage in pediatric patients must be determined on a case-by-case basis, as pediatric safety and efficacy are not well-established.

#### **Special Cases:**

- **Elderly Patients:** Start with a lower dose, usually Irbesartan 75 mg/Metoprolol Succinate 50 mg once daily.
- **Patients with Renal Impairment:** Dosage reduction or less frequent administration might be required based on the severity of impairment.
- **Patients with Hepatic Dysfunction:** Careful monitoring is essential, with possible dosage adjustments.
- **Patients with Comorbid Conditions:** For patients with diabetes, congestive heart failure, or asthma, meticulous consideration and dosage adjustments are needed.

### **Clinical Use Cases**

Dosages below are usual initial amounts and may need modifications based on patient status and clinical response:

- **Intubation:** Exercise caution as beta-blockers can exacerbate certain conditions.
- **Surgical Procedures:** Careful evaluation and management are necessary.
- **Mechanical Ventilation:** Exercise caution due to potential interaction with respiratory function.
- **Intensive Care Unit (ICU) Use:**  Dosage adjustments and careful monitoring are crucial.
- **Emergency Situations:** Individualized dosing determined by the situation and patient condition.


### **Dosage Adjustments**

Dosage modifications are based on individual patient factors, such as renal or hepatic dysfunction, metabolic disorders, or genetic polymorphisms affecting drug metabolism.


## **Side Effects**


### **Common Side Effects**

- Dizziness
- Fatigue
- Headache
- Nausea
- Slow heart rate


### **Rare but Serious Side Effects**

- Angioedema (swelling of face, lips, tongue, or throat)
- Difficulty breathing
- Kidney dysfunction
- Severe hypotension
- Worsening heart failure


### **Long-Term Effects**

- Potential for worsening pre-existing heart conditions
- Kidney problems


### **Adverse Drug Reactions (ADR)**

- Severe allergic reactions
- Bradycardia (slow heart rate)
- Hypotension (low blood pressure)




## **Contraindications**

- Hypersensitivity to irbesartan, metoprolol, or any components of the formulation.
- Second- or third-degree atrioventricular block (unless a pacemaker is present)
- Severe bradycardia
- Cardiogenic shock
- Decompensated heart failure
- Sick sinus syndrome (unless a pacemaker is present)



## **Drug Interactions**

- Other antihypertensive medications (additive effect)
- Calcium channel blockers (can further slow heart rate)
- Digoxin (can elevate digoxin levels)
- Insulin or oral hypoglycemic agents (can mask signs of hypoglycemia)
- NSAIDs (can reduce the antihypertensive effect)
- CYP2D6 inhibitors (can increase metoprolol levels)


## **Pregnancy and Breastfeeding**

- **Pregnancy:** Irbesartan is contraindicated during the second and third trimesters due to potential fetal harm. Metoprolol should be used cautiously during pregnancy, only if clearly needed, and with close fetal monitoring.
- **Breastfeeding:** Metoprolol is excreted in breast milk and may pose a risk to the nursing infant.  Irbesartan is not recommended during breastfeeding.


## **Drug Profile Summary**

- **Mechanism of Action:** ARB + Beta-blocker. Irbesartan blocks angiotensin II receptors, while metoprolol blocks beta-1 receptors.
- **Side Effects:** Dizziness, fatigue, headache, nausea, bradycardia.
- **Contraindications:** Hypersensitivity, heart block, severe bradycardia, cardiogenic shock.
- **Drug Interactions:** Other antihypertensives, calcium channel blockers, digoxin, insulin, NSAIDs.
- **Pregnancy & Breastfeeding:** Use with caution during pregnancy; not recommended while breastfeeding.
- **Dosage:** Initial dose: one tablet Irbesartan 150 mg/Metoprolol Succinate 100 mg once daily.
- **Monitoring Parameters:** Blood pressure, heart rate, potassium levels, renal function, hepatic function.



## **Popular Combinations**

Irbesartan + Metoprolol Succinate is a frequently used combination.  Additional combinations depend on the patient's specific needs.



## **Precautions**

- **General Precautions:** Pre-screening for allergies, metabolic disorders, and organ dysfunction is recommended.
- **Specific Populations:** Refer to dosage adjustments for pregnant women, breastfeeding mothers, children, and the elderly.
- **Lifestyle Considerations:** Alcohol consumption should be limited. Patients should be advised about potential dizziness and its impact on driving or operating machinery.


## **FAQs (Frequently Asked Questions)**

### **Q1: What is the recommended dosage for Irbesartan + Metoprolol Succinate?**

**A:** The standard starting dose for adults is one tablet of 150 mg irbesartan/100 mg metoprolol succinate once daily. Dosage may be adjusted based on individual patient response.  This combination is not typically recommended for children.

### **Q2: What are the main side effects of this drug?**

**A:** Common side effects include dizziness, fatigue, headache, nausea, and slow heart rate.

### **Q3: Are there any serious side effects to be aware of?**

**A:** Yes, rare but serious side effects may include angioedema, kidney dysfunction, and worsening heart failure.

### **Q4: What are the contraindications for this drug?**

**A:** Contraindications include hypersensitivity to the drug components, heart block, severe bradycardia, cardiogenic shock, and decompensated heart failure.

### **Q5: Can this drug be used during pregnancy or breastfeeding?**

**A:** Irbesartan is contraindicated during the second and third trimesters of pregnancy.  Metoprolol should be used with caution and only if the potential benefit outweighs the risk. Neither drug is generally recommended during breastfeeding.

### **Q6:  What other drugs should be avoided while taking Irbesartan + Metoprolol Succinate?**

**A:** Concomitant use of other antihypertensives, calcium channel blockers, digoxin, insulin, NSAIDs, and CYP2D6 inhibitors may lead to drug interactions and should be carefully managed.


### **Q7: How should I monitor a patient on Irbesartan + Metoprolol Succinate?**

**A:** Monitor blood pressure, heart rate, potassium levels, renal function, and hepatic function regularly.

### **Q8: What is the mechanism of action of this combination?**

**A:** Irbesartan blocks angiotensin II receptors, while metoprolol blocks beta-1 receptors, leading to vasodilation and reduced cardiac output.

### **Q9:  Is this combination safe for patients with diabetes?**

**A:** It can be used in patients with diabetes, but careful monitoring of blood sugar and dose adjustments may be necessary. The combination may mask some symptoms of hypoglycemia.

### **Q10: What should I do if a patient experiences dizziness while taking this medication?**

**A:** Advise the patient to sit or lie down until the dizziness subsides.  Caution them against driving or operating machinery while experiencing dizziness.  Consider a dose adjustment if dizziness persists.

